Updated analysis of the Phase III CASPIAN trial showed Imfinzi (durvalumab) alongside a choice of chemotherapies demonstrated a sustained, clinically-meaningful overall survival (OS) benefit as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC).
Data on the AstraZeneca (LSE: AZN) drug in combination with etoposide plus either carboplatin or cisplatin was presented at the 2020 American Society of Clinical Oncology (ASCO20) Virtual Scientific Program.
This data showed that 11% of patients on Imfinzi plus chemotherapy had not progressed and remained on treatment at two years, versus 2.9% on chemotherapy alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze